Completed PHASE1 INTERVENTIONAL 2-arm NCT01848821

The Effect of OASIS Ultra on Critical Sized Wound Healing

Pilot Study of the Effect of OASIS Ultra on Critical Sized Wound Healing

Sponsor: Massachusetts General Hospital

Conditions Iatrogenic Critical Sized Wound Defects Infective Wound Traumatic Wound Wound Healing

Interventions OASIS Ultra Wound VAC Standard Therapy

Updated 10 times since 2017 Last updated: Oct 25, 2019 Started: May 31, 2013 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01848821, this PHASE1 trial focuses on Iatrogenic Critical Sized Wound Defects and Infective Wound and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Dec 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Nov 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Nov 2019 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States